In recent years, cannabidiol (CBD) has emerged from the shadows of its association with cannabis to become a widely marketed product with a growing consumer base, especially among youth populations. A groundbreaking cross-sectional study conducted in Spain has now shed light on the trends, perceptions, and potential implications of over-the-counter (OTC) CBD product use among young individuals. This comprehensive research, soon to be published in the International Journal of Mental Health and Addiction, navigates through the complex landscape surrounding CBD’s accessibility, youth engagement, and the regulatory challenges emblematic of this novel market.
CBD, a non-psychoactive compound derived primarily from the hemp plant, differs significantly from tetrahydrocannabinol (THC), the psychotropic component commonly linked to cannabis products. Its therapeutic claims span a broad spectrum, from anxiety relief to anti-inflammatory effects, garnering both public interest and scientific scrutiny. Despite the surge in popularity, especially among younger demographics, the scientific community remains cautious due to inconclusive evidence about long-term effects, dosage standardization, and potential psychological and physiological risks.
The recent study utilized a cross-sectional design to survey a large cohort of Spanish youth, unveiling nuanced insights into how and why young consumers are turning to OTC CBD products. The methodology incorporated standardized questionnaires, assessing usage patterns, motivations for consumption, perceived benefits, and awareness of potential risks. It also evaluated psychological correlates such as anxiety levels and their relationship to CBD consumption, thereby providing a multifaceted view of this emerging trend.
A key revelation from the study is the predominance of OTC CBD product use as a self-managed strategy to alleviate subclinical symptoms related to mental health, particularly anxiety and sleep disturbances. This indicates a significant gap in formal mental health support systems and an urgent need for evidence-based interventions targeted toward young populations. The ease of access to CBD products through pharmacies, health shops, and even general retail channels without stringent age restrictions complicates regulatory oversight.
Notably, while the majority of participants reported perceived positive effects, including relaxation and improved sleep quality, a concerning minority acknowledged adverse reactions such as gastrointestinal discomfort and transient mood alterations. These findings underscore the importance of rigorous pharmacovigilance and consumer education as the market for CBD products expands. The study highlights the tension between consumer autonomy and public health imperatives, particularly in the context of adolescent neurodevelopment and vulnerability.
Moreover, the regulatory framework surrounding CBD products in Spain, as in many other countries, is marked by ambiguities. The European Union’s stance on CBD as a novel food and medicinal product leaves regulatory bodies with the challenging task of balancing innovation, commerce, and safety. The study’s authors call for clearer policies, emphasizing mandatory quality controls, accurate labeling, and restrictions on marketing claims that might mislead young consumers or downplay potential risks.
The social and psychological dimensions of CBD use among youth also came under scrutiny. The study discusses the influence of peer dynamics, social media, and cultural narratives that often glamorize CBD as a harmless wellness panacea. This phenomenon contributes to normalization, potentially obscuring the need for critical appraisal and medical guidance. The researchers advocate for targeted educational campaigns that provide balanced information and promote informed decision-making.
Technological advances have facilitated an explosion in product diversity, encompassing oils, edibles, beverages, cosmetics, and more. The chemical heterogeneity of these products, combined with varying extraction methods and concentrations, introduces challenges both for consumers seeking consistency and healthcare providers aiming to offer guidance. The study underscores the necessity of standardized analytical methods to ensure reproducibility and safety across product batches.
From a pharmacological perspective, CBD’s interaction with the endocannabinoid system is complex and not fully elucidated. Its mechanisms involve modulation of neurotransmitter release, anti-inflammatory pathways, and anxiolytic effects through serotonergic activity among others. However, the potential for drug interactions, particularly with medications metabolized by cytochrome P450 enzymes, remains poorly characterized in the context of widespread OTC use.
Importantly, the research draws attention to gaps in clinical evidence regarding the dose-response relationship of CBD, particularly in subpopulations such as adolescents. Over-the-counter products often lack verified dosing information, leading to inconsistent usage and challenges in risk-benefit assessment. This reinforces calls for clinical trials that specifically address the safety and efficacy of CBD in youth cohorts.
The mental health implications of widespread CBD use also reflect broader societal challenges. As traditional healthcare services grapple with increasing demand, some young people may be turning to readily available CBD products as a form of self-medication or escape. The study recalls cautionary parallels with other psychoactive substances and emphasizes the importance of integrated public health strategies that incorporate education, regulation, and support services.
While the research was limited to Spain, its findings resonate globally as similar patterns emerge in other European countries and beyond. Cross-national studies could further elucidate cultural, legal, and healthcare system variables affecting CBD usage trends. The study authors encourage international collaboration to harmonize regulatory standards and promote responsible consumption practices.
In conclusion, this pivotal study offers a timely and data-driven perspective on the evolving landscape of over-the-counter CBD product use among youth. It balances optimism about CBD’s potential therapeutic benefits with sober recognition of the challenges posed by regulatory gaps, information asymmetry, and unknown long-term effects. Ongoing research coupled with pragmatic policy action will be crucial to safeguarding public health while harnessing the promise of cannabinoid science.
This study marks a critical step forward in understanding the complex intersection of youth behavior, emerging wellness trends, and regulatory science. By illuminating the drivers, risks, and perceptions surrounding OTC CBD use, González-Roz and colleagues contribute essential knowledge that will inform clinicians, policymakers, and consumers alike. As the dialogue around cannabinoids evolves, such empirical evidence is invaluable for shaping safe, effective, and responsible frameworks for this burgeoning market.
Subject of Research: Use of over-the-counter cannabidiol (CBD) products among youth and their perceptions, usage patterns, and regulatory concerns in Spain.
Article Title: A Cross-Sectional Study on Youth and Over-the-Counter CBD Products: Understanding the Current Landscape in Spain.
Article References:
González-Roz, A., Secades-Villa, R., Alemán-Moussa, L. et al. A Cross-Sectional Study on Youth and Over-the-Counter CBD Products: Understanding the Current Landscape in Spain. Int J Ment Health Addiction (2025). https://doi.org/10.1007/s11469-025-01494-2
Image Credits: AI Generated
